Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
IMFINZI (AstraZeneca Pty Ltd)
Product name
IMFINZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
235 working days (255)
Active ingredients
durvalumab (rch)
Registration type
NCE/NBE
Indication
IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy